Brooks Leitner, MD/PhD, newest partner at PsyMed Ventures and expert in neuroscience from Yale and the NIH, discusses the future of brain health investments. He emphasizes a human-first approach, shifting from animal models to clinical insights. The conversation covers emerging investment areas like therapeutics, diagnostics, and AI-enabled care. Brooks also shares his thoughts on leadership challenges, innovative strategies in personal health, and the evolving landscape of mental health innovations that can reshape therapies and enhance patient care.